SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

West Pharmaceutical Services Inc. – ‘10-Q’ for 3/31/22 – ‘EX-101.CAL’

On:  Thursday, 4/28/22, at 4:04pm ET   ·   For:  3/31/22   ·   Accession #:  105770-22-17   ·   File #:  1-08036

Previous ‘10-Q’:  ‘10-Q’ on 10/28/21 for 9/30/21   ·   Next:  ‘10-Q’ on 7/28/22 for 6/30/22   ·   Latest:  ‘10-Q’ on 4/25/24 for 3/31/24   ·   7 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/28/22  West Pharmaceutical Services Inc. 10-Q        3/31/22   84:7.8M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    756K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
11: R1          Cover                                               HTML     75K 
12: R2          Condensed Consolidated Statements of Income         HTML     99K 
                (Unaudited)                                                      
13: R3          Condensed Consolidated Statements of Comprehensive  HTML     51K 
                Income (Unaudited)                                               
14: R4          Condensed Consolidated Statements of Comprehensive  HTML     27K 
                Income (Unaudited) (Parenthetical)                               
15: R5          Condensed Consolidated Balance Sheets (Unaudited)   HTML    156K 
16: R6          Condensed Consolidated Balance Sheets (Unaudited)   HTML     40K 
                (Parenthetical)                                                  
17: R7          Condensed Consolidated Statements of Cash Flows     HTML     92K 
                (Unaudited)                                                      
18: R8          Basis of Presentation and Summary of Significant    HTML     27K 
                Accounting Policies                                              
19: R9          New Accounting Standards                            HTML     35K 
20: R10         Revenue                                             HTML     53K 
21: R11         Net Income Per Share                                HTML     33K 
22: R12         Inventories                                         HTML     30K 
23: R13         Leases                                              HTML     52K 
24: R14         Affiliated Companies                                HTML     27K 
25: R15         Debt                                                HTML     45K 
26: R16         Derivative Financial Instruments                    HTML     92K 
27: R17         Fair Value Measurements                             HTML     82K 
28: R18         Accumulated Other Comprehensive Loss                HTML     86K 
29: R19         Shareholders' Equity                                HTML    108K 
30: R20         Stock-Based Compensation                            HTML     27K 
31: R21         Benefit Plans                                       HTML     80K 
32: R22         Other (Income) Expense                              HTML     48K 
33: R23         Income Taxes                                        HTML     27K 
34: R24         Commitments and Contingencies                       HTML     26K 
35: R25         Segment Information                                 HTML     59K 
36: R26         Basis of Presentation and Summary of Significant    HTML     30K 
                Accounting Policies (Policies)                                   
37: R27         Revenue (Tables)                                    HTML     50K 
38: R28         Net Income Per Share (Tables)                       HTML     31K 
39: R29         Inventories (Tables)                                HTML     31K 
40: R30         Leases (Tables)                                     HTML     55K 
41: R31         Debt (Tables)                                       HTML     35K 
42: R32         Derivative Financial Instruments (Tables)           HTML     93K 
43: R33         Fair Value Measurements (Tables)                    HTML     75K 
44: R34         Accumulated Other Comprehensive Loss (Tables)       HTML     87K 
45: R35         Shareholders' Equity (Tables)                       HTML    104K 
46: R36         Benefit Plans (Tables)                              HTML     73K 
47: R37         Other (Income) Expense (Tables)                     HTML     47K 
48: R38         Segment Information (Tables)                        HTML     55K 
49: R39         Revenue - Revenue Recognition (Details)             HTML     55K 
50: R40         Revenue - Contracts and Liabilities (Details)       HTML     33K 
51: R41         Revenue - Contracts and Liabilities, Narrative      HTML     34K 
                (Details)                                                        
52: R42         Net Income Per Share (Details)                      HTML     54K 
53: R43         Inventories (Details)                               HTML     31K 
54: R44         Leases - Lease Cost (Details)                       HTML     31K 
55: R45         Leases - Lease Cash Flow and Supplemental           HTML     27K 
                Information (Details)                                            
56: R46         Leases - Lease Weighted Average (Details)           HTML     26K 
57: R47         Leases - Maturities of Operating Lease Liabilities  HTML     45K 
                (Details)                                                        
58: R48         Affiliated Companies (Details)                      HTML     36K 
59: R49         Debt - Long-term Debt (Details)                     HTML     47K 
60: R50         Debt - Credit Facility (Details)                    HTML     78K 
61: R51         Derivative Financial Instruments - Foreign          HTML     64K 
                Exchange Rate Risk (Details)                                     
62: R52         Derivative Financial Instruments - Effects of       HTML     81K 
                Derivative Instruments on OCI and Earnings                       
                (Details)                                                        
63: R53         Fair Value Measurements - Assets and Liabilities    HTML     69K 
                Recorded at Fair Value (Details)                                 
64: R54         Fair Value Measurements - Other Financial           HTML     26K 
                Instruments (Details)                                            
65: R55         Accumulated Other Comprehensive Loss - Components   HTML     53K 
                of Accumulated Other Comprehensive Income                        
                (Details)                                                        
66: R56         Accumulated Other Comprehensive Loss - Other        HTML     78K 
                Comprehensive Loss Reclassifications (Details)                   
67: R57         Shareholders' Equity - Change in Shareholders'      HTML     74K 
                Equity (Details)                                                 
68: R58         Shareholders' Equity - Supplemental Equity          HTML     24K 
                Information (Details)                                            
69: R59         Stock-Based Compensation (Details)                  HTML     60K 
70: R60         Benefit Plans - Schedule of Components of Net       HTML     61K 
                Periodic Benefit Cost (Details)                                  
71: R61         Benefit Plans - Narrative (Details)                 HTML     27K 
72: R62         Other (Income) Expense - Schedule of Other          HTML     36K 
                (Income) Expense (Details)                                       
73: R63         Other (Income) Expense - Narrative (Details)        HTML     37K 
74: R64         Other (Income) Expense - Schedule of Restructuring  HTML     37K 
                and Related Charges (Details)                                    
75: R65         Other (Income) Expense - Other Items (Details)      HTML     32K 
76: R66         Income Taxes (Details)                              HTML     33K 
77: R67         Segment Information - Narrative (Details)           HTML     23K 
78: R68         Segment Information - Sales by Product Group        HTML     39K 
                (Details)                                                        
79: R69         Segment Information - Segment Financial             HTML     52K 
                Information (Details)                                            
82: XML         IDEA XML File -- Filing Summary                      XML    149K 
80: XML         XBRL Instance -- wst-20220331_htm                    XML   2.17M 
81: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
 7: EX-101.CAL  XBRL Calculations -- wst-20220331_cal                XML    206K 
 8: EX-101.DEF  XBRL Definitions -- wst-20220331_def                 XML    472K 
 9: EX-101.LAB  XBRL Labels -- wst-20220331_lab                      XML   1.44M 
10: EX-101.PRE  XBRL Presentations -- wst-20220331_pre               XML    849K 
 6: EX-101.SCH  XBRL Schema -- wst-20220331                          XSD    136K 
83: JSON        XBRL Instance as JSON Data -- MetaLinks              423±   584K 
84: ZIP         XBRL Zipped Folder -- 0000105770-22-000017-xbrl      Zip    249K

‘EX-101.CAL’   —   XBRL Calculations — wst-20220331_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL Document Created with Wdesk from Workiva -->
<!-- Copyright 2022 Workiva -->
<!-- r:bc31ed0b-ee00-456b-a007-12251f5174cb,g:81905d62-be14-4bd9-ba09-a863dc1b6c92 -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="wst-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55ed8f05-da16-450e-ab30-3bbcf19ffae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8764b15b-69b5-4331-b0d4-ea98cfbf7b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55ed8f05-da16-450e-ab30-3bbcf19ffae2" xlink:to="loc_us-gaap_OperatingIncomeLoss_8764b15b-69b5-4331-b0d4-ea98cfbf7b17" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_32e62f41-5e92-44a8-a441-1c50fdf65b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55ed8f05-da16-450e-ab30-3bbcf19ffae2" xlink:to="loc_us-gaap_InterestExpense_32e62f41-5e92-44a8-a441-1c50fdf65b8c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_04df7a05-2b8b-4dd4-bae7-6738947da508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55ed8f05-da16-450e-ab30-3bbcf19ffae2" xlink:to="loc_us-gaap_InvestmentIncomeNet_04df7a05-2b8b-4dd4-bae7-6738947da508" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f04ddd54-e10e-48c7-96cb-5b7235969dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55ed8f05-da16-450e-ab30-3bbcf19ffae2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f04ddd54-e10e-48c7-96cb-5b7235969dfb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4eb4475e-9edf-4a01-aee0-faffd0422a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f06ee285-a06c-4a57-a86e-33d8768830db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4eb4475e-9edf-4a01-aee0-faffd0422a26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f06ee285-a06c-4a57-a86e-33d8768830db" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_1e5da5d3-5ffc-4079-b225-024921bb4e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4eb4475e-9edf-4a01-aee0-faffd0422a26" xlink:to="loc_us-gaap_GrossProfit_1e5da5d3-5ffc-4079-b225-024921bb4e2b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2c68ee07-30a0-4c64-b871-347b7b888e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4eb4475e-9edf-4a01-aee0-faffd0422a26" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2c68ee07-30a0-4c64-b871-347b7b888e42" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense_2120ca9d-6370-4f56-955e-686b9dcbcdd4" xlink:href="wst-20220331.xsd#wst_OtherIncomeExpense"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4eb4475e-9edf-4a01-aee0-faffd0422a26" xlink:to="loc_wst_OtherIncomeExpense_2120ca9d-6370-4f56-955e-686b9dcbcdd4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_154b4647-b24c-40c8-aa3b-9e90f5300c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_36f5f7b9-5da0-4725-b9c0-91fe49862224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_154b4647-b24c-40c8-aa3b-9e90f5300c55" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_36f5f7b9-5da0-4725-b9c0-91fe49862224" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47affcc0-9509-4ed3-a49e-ad29d4274ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_154b4647-b24c-40c8-aa3b-9e90f5300c55" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47affcc0-9509-4ed3-a49e-ad29d4274ab7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_03f0085c-d8aa-46d4-9641-e4de46ade165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_154b4647-b24c-40c8-aa3b-9e90f5300c55" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_03f0085c-d8aa-46d4-9641-e4de46ade165" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_66ec312c-8f53-4afe-8457-94ae480e6372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_532e58fa-879e-4ada-b5b4-5eaa79884146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_66ec312c-8f53-4afe-8457-94ae480e6372" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_532e58fa-879e-4ada-b5b4-5eaa79884146" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ae79494d-3ebb-477b-812e-bb5f7b2191be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_66ec312c-8f53-4afe-8457-94ae480e6372" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ae79494d-3ebb-477b-812e-bb5f7b2191be" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="wst-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6abf3ebb-a65f-484b-b8cc-abc3df2e4144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_31f92c58-2a1e-4f92-8e2b-2d4539876d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6abf3ebb-a65f-484b-b8cc-abc3df2e4144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_31f92c58-2a1e-4f92-8e2b-2d4539876d43" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_39525f16-f79b-4a7f-94c3-6fb6390a00c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6abf3ebb-a65f-484b-b8cc-abc3df2e4144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_39525f16-f79b-4a7f-94c3-6fb6390a00c4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bfd58dbd-66bb-406d-8764-0eaf0f490747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6abf3ebb-a65f-484b-b8cc-abc3df2e4144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bfd58dbd-66bb-406d-8764-0eaf0f490747" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_610051ae-18f6-4ebc-9268-ae5fb27ec926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f377e63-5564-46dd-a31b-24cbc07c6eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_610051ae-18f6-4ebc-9268-ae5fb27ec926" xlink:to="loc_us-gaap_NetIncomeLoss_4f377e63-5564-46dd-a31b-24cbc07c6eba" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aadfd037-f388-4363-b554-0e23aea18341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_610051ae-18f6-4ebc-9268-ae5fb27ec926" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aadfd037-f388-4363-b554-0e23aea18341" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="wst-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_233f9f68-3bc1-44e5-a1f5-2d69627b0603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3e2e1cae-5249-4a2f-bff2-5b38d095d87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_233f9f68-3bc1-44e5-a1f5-2d69627b0603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3e2e1cae-5249-4a2f-bff2-5b38d095d87e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27613a84-e57b-4200-bf6f-c805a60a1b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_233f9f68-3bc1-44e5-a1f5-2d69627b0603" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27613a84-e57b-4200-bf6f-c805a60a1b81" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a59ce123-0833-466f-8c1a-ceeeef69a378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_LiabilitiesCurrent_a59ce123-0833-466f-8c1a-ceeeef69a378" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_91a3a730-6b4c-4422-ad89-f7aa8ed55097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_91a3a730-6b4c-4422-ad89-f7aa8ed55097" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_baddf476-6d2d-40dc-95ae-6d5041bd660f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_baddf476-6d2d-40dc-95ae-6d5041bd660f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_57570c19-d511-4d7f-bed9-323b73b8fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_57570c19-d511-4d7f-bed9-323b73b8fe98" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb9316cc-8cca-4f4b-ae54-dd7c6e85e245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb9316cc-8cca-4f4b-ae54-dd7c6e85e245" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cae4763b-cc51-451d-a34b-84a5a273b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cae4763b-cc51-451d-a34b-84a5a273b7f4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_2e1d362b-2e30-4dd7-bfb0-4a98391a3e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee4f03c7-bb34-4436-a80c-37dc2c6f4c50" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_2e1d362b-2e30-4dd7-bfb0-4a98391a3e65" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_wst_AccruedSalariesWagesAndBenefitsCurrent_cc0160e8-7a66-4dd6-8d7e-bff716b6fbed" xlink:href="wst-20220331.xsd#wst_AccruedSalariesWagesAndBenefitsCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_wst_AccruedSalariesWagesAndBenefitsCurrent_cc0160e8-7a66-4dd6-8d7e-bff716b6fbed" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_wst_NotesPayableAndOtherDebtCurrent_d9794a03-0ae0-49b4-9583-f66deabebe7d" xlink:href="wst-20220331.xsd#wst_NotesPayableAndOtherDebtCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_wst_NotesPayableAndOtherDebtCurrent_d9794a03-0ae0-49b4-9583-f66deabebe7d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8ea4f1f4-d7dc-4ca4-bf0c-85c368bab271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_us-gaap_AccountsPayableCurrent_8ea4f1f4-d7dc-4ca4-bf0c-85c368bab271" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1b017e13-c21c-4f8a-a28d-ea83cf9ebee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1b017e13-c21c-4f8a-a28d-ea83cf9ebee7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f927ce10-866e-4380-a81a-215ef842cf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f927ce10-866e-4380-a81a-215ef842cf3e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8399ed2e-9ecf-4aff-99ee-ea6e2cc847af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8399ed2e-9ecf-4aff-99ee-ea6e2cc847af" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_64985a90-f782-4d4b-8b08-8adb2f6fd96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_146b2f5b-dc2a-4b19-8e39-421ec123e4d2" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_64985a90-f782-4d4b-8b08-8adb2f6fd96a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_07d70faa-4163-4c26-a030-4c6cb638c8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:to="loc_us-gaap_PreferredStockValue_07d70faa-4163-4c26-a030-4c6cb638c8cb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5d5ba6b4-e99a-42b4-bbb7-d0d92f5cf8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:to="loc_us-gaap_CommonStockValue_5d5ba6b4-e99a-42b4-bbb7-d0d92f5cf8d9" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5b538a48-5a33-437b-a1fb-dd2de199e9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5b538a48-5a33-437b-a1fb-dd2de199e9b4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33a28cdb-d7d2-48d9-acd6-abca78b65898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33a28cdb-d7d2-48d9-acd6-abca78b65898" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b4044721-32db-499a-ba21-1acb25082358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b4044721-32db-499a-ba21-1acb25082358" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c2eed7ba-84a1-453e-be93-252b004ed2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_292a67f8-be3d-4def-962c-0c9e64cfe08a" xlink:to="loc_us-gaap_TreasuryStockValue_c2eed7ba-84a1-453e-be93-252b004ed2f7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b18a137-d831-4899-90ac-6d78943a6010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_75a8e82e-e0c1-4536-8f3d-20f3309c56c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b18a137-d831-4899-90ac-6d78943a6010" xlink:to="loc_us-gaap_Liabilities_75a8e82e-e0c1-4536-8f3d-20f3309c56c8" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8bbef8be-9ad1-43a1-8fa2-4ce238a01aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b18a137-d831-4899-90ac-6d78943a6010" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8bbef8be-9ad1-43a1-8fa2-4ce238a01aa2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e0a0133-994c-4abc-8692-71b7de648c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b18a137-d831-4899-90ac-6d78943a6010" xlink:to="loc_us-gaap_StockholdersEquity_9e0a0133-994c-4abc-8692-71b7de648c61" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d20b597-bbcd-471f-a059-586eb2d10920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd9589eb-f31e-4cd2-b0d0-073d06e37389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d20b597-bbcd-471f-a059-586eb2d10920" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd9589eb-f31e-4cd2-b0d0-073d06e37389" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_edc367d4-7133-47a5-8ec4-460ab4fef2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d20b597-bbcd-471f-a059-586eb2d10920" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_edc367d4-7133-47a5-8ec4-460ab4fef2be" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_97d7d28e-6ece-488e-b2f0-6b1856b0d742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d20b597-bbcd-471f-a059-586eb2d10920" xlink:to="loc_us-gaap_InventoryNet_97d7d28e-6ece-488e-b2f0-6b1856b0d742" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_319be31f-3180-4e18-b71b-598c256f39cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d20b597-bbcd-471f-a059-586eb2d10920" xlink:to="loc_us-gaap_OtherAssetsCurrent_319be31f-3180-4e18-b71b-598c256f39cb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0387a7cb-0919-4b5e-b652-4cca05c4d4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_AssetsCurrent_0387a7cb-0919-4b5e-b652-4cca05c4d4ed" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e9094ec-23d6-4324-886e-19b8bbf2efa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e9094ec-23d6-4324-886e-19b8bbf2efa3" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52305eca-6885-4745-bc44-10292a9268e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52305eca-6885-4745-bc44-10292a9268e9" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_5e12e58d-7050-4d85-b8a2-52404ca5a23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_5e12e58d-7050-4d85-b8a2-52404ca5a23f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_27a65c98-6f79-4a55-8584-4e3c889b2525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_Goodwill_27a65c98-6f79-4a55-8584-4e3c889b2525" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0b9b5a9a-c98e-46e4-8528-f23cf85922ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0b9b5a9a-c98e-46e4-8528-f23cf85922ec" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_16ae9fb6-1b7b-49db-8c31-6edec6dc8b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_16ae9fb6-1b7b-49db-8c31-6edec6dc8b2d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0f173093-8232-46a1-962d-935cf0febd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0f173093-8232-46a1-962d-935cf0febd97" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b688aefe-5b71-42d1-8fe9-796ff9da5d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51c31527-c9cf-498c-ae57-0f95667aa9a8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b688aefe-5b71-42d1-8fe9-796ff9da5d65" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="wst-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d4a1546-3975-4e3d-998a-c33ce0827091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_NetIncomeLoss_9d4a1546-3975-4e3d-998a-c33ce0827091" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_62e28cb0-76a4-4768-ab89-bfd2e3e96e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_Depreciation_62e28cb0-76a4-4768-ab89-bfd2e3e96e3c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_a88fea21-c2c7-4b9b-9a27-c223e731f9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_AdjustmentForAmortization_a88fea21-c2c7-4b9b-9a27-c223e731f9a3" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0e0be0b2-934e-4367-b90b-9b07fc4975cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_ShareBasedCompensation_0e0be0b2-934e-4367-b90b-9b07fc4975cb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_abcadb0d-87dd-45f6-b410-b9fd3ad161da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_abcadb0d-87dd-45f6-b410-b9fd3ad161da" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9e9f2a1d-169c-40ab-9058-d4d3a9bd4205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9e9f2a1d-169c-40ab-9058-d4d3a9bd4205" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ca9ab188-9186-4571-b33b-6c0ac04777cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ca9ab188-9186-4571-b33b-6c0ac04777cf" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_0040c53a-5edd-411d-9e45-b57710d26aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2760259e-2628-4ea2-84e4-afd8401c69e8" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_0040c53a-5edd-411d-9e45-b57710d26aa6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97a80b8a-4b70-44c7-84ba-c09e09355ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3405da4-3476-498e-821b-1e56e32ddf99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97a80b8a-4b70-44c7-84ba-c09e09355ac3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3405da4-3476-498e-821b-1e56e32ddf99" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe887b27-d85c-4256-87fa-7ea965d4fe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97a80b8a-4b70-44c7-84ba-c09e09355ac3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe887b27-d85c-4256-87fa-7ea965d4fe1f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcdce11e-d75f-4757-bafc-492aba81a746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97a80b8a-4b70-44c7-84ba-c09e09355ac3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcdce11e-d75f-4757-bafc-492aba81a746" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_459672aa-4a23-4979-a143-82fe0f38b238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97a80b8a-4b70-44c7-84ba-c09e09355ac3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_459672aa-4a23-4979-a143-82fe0f38b238" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4eff02eb-b82b-440c-81c3-f58b756536e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_796d9cd6-3875-4076-a6b7-6be21c4c288a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4eff02eb-b82b-440c-81c3-f58b756536e0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_796d9cd6-3875-4076-a6b7-6be21c4c288a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9b9cd120-9660-4591-ba07-afcc8dcc25c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4eff02eb-b82b-440c-81c3-f58b756536e0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9b9cd120-9660-4591-ba07-afcc8dcc25c4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_5a96c17a-797c-45b5-b5d7-4ceb00cac0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_5a96c17a-797c-45b5-b5d7-4ceb00cac0f1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ad64a396-5d0b-453a-953f-7444a5921694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ad64a396-5d0b-453a-953f-7444a5921694" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d587e54d-5c44-48c9-acc4-42f0c6eb2c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d587e54d-5c44-48c9-acc4-42f0c6eb2c13" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d3cf0793-b14b-4456-ad2d-b3006bc3bd45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d3cf0793-b14b-4456-ad2d-b3006bc3bd45" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_25fdf4a2-a745-413d-8340-82db8cfdc603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_25fdf4a2-a745-413d-8340-82db8cfdc603" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_485e681f-703b-451d-b92a-7cf7287472fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_485e681f-703b-451d-b92a-7cf7287472fb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_f5bbb99a-6735-47d8-8212-839800950bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c2d5eb8-f3c7-46ef-84e9-e394caaf2e30" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_f5bbb99a-6735-47d8-8212-839800950bf0" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#RevenueContractsandLiabilitiesNarrativeDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2a459c1f-93c2-4654-9b1c-0e04c345a522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8cbf0c88-6aa4-401a-8d39-6e7ec40a81f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_2a459c1f-93c2-4654-9b1c-0e04c345a522" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8cbf0c88-6aa4-401a-8d39-6e7ec40a81f7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_24cff309-846a-47cf-bbf7-579922cd50b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_2a459c1f-93c2-4654-9b1c-0e04c345a522" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_24cff309-846a-47cf-bbf7-579922cd50b6" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#NetIncomePerShareDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/NetIncomePerShareDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4bc9bece-346e-4c1e-89ae-caef7c297b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_732077b3-fa20-4e31-b8f6-9e154da9c865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4bc9bece-346e-4c1e-89ae-caef7c297b2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_732077b3-fa20-4e31-b8f6-9e154da9c865" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_14ba17f5-73ef-41ee-ad08-2cd9ec26edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4bc9bece-346e-4c1e-89ae-caef7c297b2c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_14ba17f5-73ef-41ee-ad08-2cd9ec26edbe" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#InventoriesDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/InventoriesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0ae7f4d7-4966-4f06-922a-341f5c4609e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10dce685-a5cc-4108-b98f-a7ce2b663059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0ae7f4d7-4966-4f06-922a-341f5c4609e7" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10dce685-a5cc-4108-b98f-a7ce2b663059" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d8129b74-5fb3-4cf9-882b-12b594bcf1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0ae7f4d7-4966-4f06-922a-341f5c4609e7" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d8129b74-5fb3-4cf9-882b-12b594bcf1bf" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_29cc1467-b027-4709-8c99-58351d03b874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0ae7f4d7-4966-4f06-922a-341f5c4609e7" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_29cc1467-b027-4709-8c99-58351d03b874" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#LeasesLeaseCostDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/LeasesLeaseCostDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b5d256ee-75bd-4afa-8558-dea14cc9d701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a94e99d1-2777-4586-82c8-fb389e01786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5d256ee-75bd-4afa-8558-dea14cc9d701" xlink:to="loc_us-gaap_OperatingLeaseCost_a94e99d1-2777-4586-82c8-fb389e01786d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_63a210d7-d3ff-4ebe-b812-8618e479e2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5d256ee-75bd-4afa-8558-dea14cc9d701" xlink:to="loc_us-gaap_ShortTermLeaseCost_63a210d7-d3ff-4ebe-b812-8618e479e2b5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_69eaa2b6-2671-4aab-93be-e2ac72bf4a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5d256ee-75bd-4afa-8558-dea14cc9d701" xlink:to="loc_us-gaap_VariableLeaseCost_69eaa2b6-2671-4aab-93be-e2ac72bf4a31" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0da43e8a-9d57-4515-b46e-f97ace8cb7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0da43e8a-9d57-4515-b46e-f97ace8cb7ce" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4a26ac4-0a4f-4d2e-9b9b-0eeec4088284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4a26ac4-0a4f-4d2e-9b9b-0eeec4088284" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4628405-d83d-4135-a64b-7612a7547f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4628405-d83d-4135-a64b-7612a7547f1f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae6fc56c-e6ed-4482-86b1-12105a7bd719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae6fc56c-e6ed-4482-86b1-12105a7bd719" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6cdf6b7f-82e0-406f-a822-40ef4342f5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6cdf6b7f-82e0-406f-a822-40ef4342f5b2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5cacabeb-cad4-43f1-9997-b6a60655649a" xlink:href="wst-20220331.xsd#wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5cacabeb-cad4-43f1-9997-b6a60655649a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_da692a81-73c6-4e20-a3ea-2b84bcbd1f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_da692a81-73c6-4e20-a3ea-2b84bcbd1f69" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a0d26671-81b3-45b3-beb1-11162ebee59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0912225b-9dc3-4473-9c72-8dd13d1da5c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a0d26671-81b3-45b3-beb1-11162ebee59c" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="wst-20220331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5645a7ce-8ea3-4aed-8e3c-ed995d6805b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80a4c32e-6742-43f3-9991-a538a334213c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5645a7ce-8ea3-4aed-8e3c-ed995d6805b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80a4c32e-6742-43f3-9991-a538a334213c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_26e06c63-8e44-4f04-a6d1-858ce7ea7d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5645a7ce-8ea3-4aed-8e3c-ed995d6805b9" xlink:to="loc_us-gaap_OperatingLeaseLiability_26e06c63-8e44-4f04-a6d1-858ce7ea7d31" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#DebtLongtermDebtDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b4fc1cca-efdd-4a87-9748-8b69d07edb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_8c94ba10-74ce-4d1a-87f7-8a29110bb907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b4fc1cca-efdd-4a87-9748-8b69d07edb53" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_8c94ba10-74ce-4d1a-87f7-8a29110bb907" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f52c5b95-5b4b-4b84-9add-14fec1f86d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b4fc1cca-efdd-4a87-9748-8b69d07edb53" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f52c5b95-5b4b-4b84-9add-14fec1f86d32" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails_1" xlink:type="simple" xlink:href="wst-20220331.xsd#DebtLongtermDebtDetails_1"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails_1" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ebe2246c-d0a0-44ed-9888-2db9a159638f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3460e7c0-d995-4703-9748-45c6c2599816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ebe2246c-d0a0-44ed-9888-2db9a159638f" xlink:to="loc_us-gaap_LongTermDebtCurrent_3460e7c0-d995-4703-9748-45c6c2599816" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d26a1aa2-5094-421f-b382-539baf419f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ebe2246c-d0a0-44ed-9888-2db9a159638f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d26a1aa2-5094-421f-b382-539baf419f87" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_637bb897-3081-4e8c-8823-b3d5a0e41a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_30e89cec-5f10-4d7e-9cba-39732f5cd3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_637bb897-3081-4e8c-8823-b3d5a0e41a27" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_30e89cec-5f10-4d7e-9cba-39732f5cd3df" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ea867b08-1e40-422d-8a5d-c64cca034737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_637bb897-3081-4e8c-8823-b3d5a0e41a27" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ea867b08-1e40-422d-8a5d-c64cca034737" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_8f3d2118-e958-4a50-90fa-e171f4f5b969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_637bb897-3081-4e8c-8823-b3d5a0e41a27" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_8f3d2118-e958-4a50-90fa-e171f4f5b969" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c43418a6-c076-45fa-995f-04bc603eb965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_91ea8a74-be5b-4254-9830-c95c5d179b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c43418a6-c076-45fa-995f-04bc603eb965" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_91ea8a74-be5b-4254-9830-c95c5d179b7a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_469809b1-7ceb-4111-b8cc-c74e7c0752e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c43418a6-c076-45fa-995f-04bc603eb965" xlink:to="loc_us-gaap_DerivativeAssets_469809b1-7ceb-4111-b8cc-c74e7c0752e2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_ff22300e-ed52-444a-a5e8-64ae3824ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationPlanAssets"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c43418a6-c076-45fa-995f-04bc603eb965" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_ff22300e-ed52-444a-a5e8-64ae3824ab56" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aedc7542-3516-40f4-9c82-3f2aa5f3eeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_560b1e06-51f0-4987-b27f-5514f75a37ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_aedc7542-3516-40f4-9c82-3f2aa5f3eeca" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_560b1e06-51f0-4987-b27f-5514f75a37ae" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ea0e9fe7-4465-4760-9e0b-530403f27d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_aedc7542-3516-40f4-9c82-3f2aa5f3eeca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ea0e9fe7-4465-4760-9e0b-530403f27d0e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_a4c6e053-742d-4850-a7a8-0b1f9f69d73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_aedc7542-3516-40f4-9c82-3f2aa5f3eeca" xlink:to="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_a4c6e053-742d-4850-a7a8-0b1f9f69d73d" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_baec389c-7b39-409f-a5b2-40dd3d2b5fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b8391eab-6f91-4c88-be17-4113fd1c91f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_baec389c-7b39-409f-a5b2-40dd3d2b5fde" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b8391eab-6f91-4c88-be17-4113fd1c91f7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_00eaf416-4e44-4374-a853-a2f24d6bc6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_baec389c-7b39-409f-a5b2-40dd3d2b5fde" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_00eaf416-4e44-4374-a853-a2f24d6bc6cc" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8eecdda6-60c8-486c-a4d6-2c07148137f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8eecdda6-60c8-486c-a4d6-2c07148137f8" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_15e4c232-9a87-4bc0-8b10-28e77f6d3bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_15e4c232-9a87-4bc0-8b10-28e77f6d3bca" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2e15c4c0-7bbe-4f91-a289-68de776c13be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2e15c4c0-7bbe-4f91-a289-68de776c13be" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_339f22cb-224d-4848-ab46-f46bbff27d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_339f22cb-224d-4848-ab46-f46bbff27d3e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4de0abf3-5f53-49f0-bd40-2b791450699e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4de0abf3-5f53-49f0-bd40-2b791450699e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d285cbad-b73a-4587-89ce-fa4aff7fde49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_96733f2f-bd69-4b39-9e92-235e7de2221c" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d285cbad-b73a-4587-89ce-fa4aff7fde49" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/OtherIncomeExpenseScheduleofOtherIncomeExpenseDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#OtherIncomeExpenseScheduleofOtherIncomeExpenseDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/OtherIncomeExpenseScheduleofOtherIncomeExpenseDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense_06a865a7-e3db-4c5d-bb39-135ecf6cce35" xlink:href="wst-20220331.xsd#wst_OtherIncomeExpense"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_25f542ed-1d9f-458e-b724-fb393dec106e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_06a865a7-e3db-4c5d-bb39-135ecf6cce35" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_25f542ed-1d9f-458e-b724-fb393dec106e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e34cfe81-0e3c-42c6-b6a9-19b62342d9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_06a865a7-e3db-4c5d-bb39-135ecf6cce35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e34cfe81-0e3c-42c6-b6a9-19b62342d9aa" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4fcfd2ff-395c-462f-ac40-c28d8361ff04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_06a865a7-e3db-4c5d-bb39-135ecf6cce35" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4fcfd2ff-395c-462f-ac40-c28d8361ff04" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_085c32f9-6219-4bc8-9d7d-ddf34969e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_06a865a7-e3db-4c5d-bb39-135ecf6cce35" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_085c32f9-6219-4bc8-9d7d-ddf34969e4e6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_019985af-8e61-404e-aae3-23a0d63a3271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_06a865a7-e3db-4c5d-bb39-135ecf6cce35" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_019985af-8e61-404e-aae3-23a0d63a3271" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="wst-20220331.xsd#SegmentInformationSegmentFinancialInformationDetails"/>
<link:calculationLink xlink:role="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0435d8f6-64b2-4039-9851-685dda7a9509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a62259fa-b5e7-48f0-91ab-0df8fef06932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0435d8f6-64b2-4039-9851-685dda7a9509" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a62259fa-b5e7-48f0-91ab-0df8fef06932" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_671656e7-9d44-4089-a907-7463cfed6bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0435d8f6-64b2-4039-9851-685dda7a9509" xlink:to="loc_us-gaap_OperatingIncomeLoss_671656e7-9d44-4089-a907-7463cfed6bcb" xlink:type="arc"/>
</link:calculationLink>
</link:linkbase>

7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/01/22  West Pharmaceutical Services Inc. 8-K:1,2,9   3/31/22   11:2.4M
 2/22/22  West Pharmaceutical Services Inc. 10-K       12/31/21  124:27M                                    Workiva Inc Wde… FA01/FA
10/28/21  West Pharmaceutical Services Inc. 10-Q        9/30/21   83:9.7M
 3/01/21  West Pharmaceutical Services Inc. 8-K:5,9     2/23/21   13:402K
 7/24/20  West Pharmaceutical Services Inc. 10-Q        6/30/20   87:11M
 4/01/19  West Pharmaceutical Services Inc. 8-K:1,2,9   3/28/19    2:3.3M
 5/06/99  West Pharmaceutical Services Inc. 10-K       12/31/98   12:372K
↑Top
Filing Submission 0000105770-22-000017   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 9, 4:45:20.2pm ET